Founders & Board of directors

Robert Rushu Luo

Board Member

Mr. Luo founded HM Capital in 2018. He has over 25 years of professional experience in investment, entrepreneurship, operations and management, life sciences research, and clinical practice.
Mr. Luo co-founded Huimei Healthcare Management Services (HM HMS) with Hillhouse Capital Group and Mayo Clinic in 2015 and has served as CEO. He then created several operating entities, such as HM Technology and HM Health under HM HMS, and serves as chairman. At the same time, he co-invested with Hillhouse in a few companies, WeDoctor, Hisun-Pfizer Pharmaceutical, Gaoji Medical, Genor Biopharma, etc.

Prior to founding HM HMS, Mr. Luo was a senior investment officer at Mayo Clinic and led multi-billion dollar investments globally, including Asia-Pacific, and invested in dozens of well-known global investment firms and healthcare companies. Earlier, Mr. Luo worked on neural stem cell research for 5 years at the Neurobiotechnology Center at the Ohio State University and completed his ophthalmology residency training at Peking Union Hospital in Beijing.

Mr. Luo received his MBA from the Ohio State University and Bachelor in Medicine from Peking University Health Science Center.

About Us

Based in Rockville, Maryland, OncoImmune is a
privately-held, clinical-stage biopharmaceutical
company that is actively engaged in the discovery
and development of biopharmaceuticals for the
treatment of cancer and autoimmune disease.

Email: This email address is being protected from spambots. You need JavaScript enabled to view it.